Rx License-Rx

TAB-2823

Focused Electrostatic Collection of Aerosol Particles for Chemical Analysis by Spectroscopic Techniques

This CDC-developed technology is an aerosol preconcentration unit (APU) designed for use with spectroscopic detection techniques, including emission, Raman, or infrared spectroscopies. Most existing pulsed microplasma techniques, such as laser-induced breakdown, for aerosols rely mainly on filter-based collection and suffer from poor accuracy, precision, and detection limits and require long sample collection times. The APU is designed to address these drawbacks by pre-concentrating the aerosol particles on a tip of a microelectrode (a few hundreds of micrometers in diameter) to allow near-real time measurements with superior accuracy and precision. The APU is designed to be small, low-pressure drop unit for its use in a battery-operated, hand-portable instrumentation. The design significantly improves accuracy and precision of measurements relative to existing methods. The APU can be integrated with a microplasma source (such as a...

Intelligence Memo

Owner: National Institutes of Health

Core category: Therapeutics

Therapeutic area: Inflammation

Indication: Pulmonology

Modality: Biologic

Focus tags: Inflammation, Ophthalmology, Oncology, Infectious Disease, Cardiometabolic

Technology tags: Biologic, Diagnostic / Biomarker, AI / ML

Mechanism:

Development stage: Preclinical

Patent status: Issued

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Inflammation. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be preclinical and is associated with National Institutes of Health. The practical first use case is Pulmonology. Public description: This CDC-developed technology is an aerosol preconcentration unit (APU) designed for use with spectroscopic detection techniques, including emission, Raman, or infrared spectroscopies. Most existing pulsed microplasma techniques, such as.

What is exciting

Already past pure discovery: Preclinical validation gives a buyer something concrete to reproduce, optimize, or package into an IND-enabling plan.

Oncology remains highly partnerable: Pharma buyers still pay attention when an asset can be tied to biomarkers, combinations, resistance biology, or a defined tumor segment.

The eye can create faster proof: Local delivery, imaging endpoints, and smaller patient groups can make ophthalmology assets easier to de-risk than broad systemic programs.

Can sell into pharma before reimbursement: A biomarker or AI tool can create value as trial enrichment, patient stratification, or translational support before becoming a regulated diagnostic.

Negatives / diligence concerns

Translation still unproven: Animal or lab data may not predict human performance; tox, PK/PD, CMC, and indication selection still need diligence.

Validation can be harder than the demo: Models and biomarkers need locked datasets, external validation, clinical utility, data rights, and a regulatory/reimbursement plan.

Competitive field may be crowded: Oncology buyers will ask why this is better than existing modalities, combinations, and biomarker strategies already in the clinic.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Inflammation wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets Merck — Checkpoint-franchise adjacency and combination-trial appetite. AstraZeneca — Oncology breadth plus interest in biomarker-defined populations. Roche / Genentech — Diagnostics plus oncology translational machinery.

Development Strategy to Increase PoS

First indication: Pulmonology

Study design: Retrospective locked-dataset validation followed by one prospective pharma enrichment pilot.

Key experiments Validate the AI-optimized pivot: Reframe as a localized orphan-retina or front-of-eye precision program Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed: Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Reframe as a localized orphan-retina or front-of-eye precision program

Best next experiment: Run the smallest independent study that validates: Switch from systemic exposure to intravitreal, topical, or depot delivery and use OCT/ERG/imaging biomarkers as early go/no-go endpoints.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.